ArticleMicrobiology spectrum2026
Aminoquinoline surfen inhibits pseudorabies virus attachment by preventing the binding of glycoprotein C to heparan sulfate.
Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bovine Lactoferrin Inhibits Pseudorabies Virus Attachment Through Blockade of Glycoprotein C-Heparan Sulfate Interaction.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Pseudorabies virus (PRV) is an important herpesvirus that infects pigs and many other animals. PRV can also infect humans, but the relevant reports are still very rare. PRV is not only a serious concern in veterinary medicine, but also a potential threat to public health. Thus, the development of effective antiviral agents against PRV is needed for its prevention and control. PRV utilizes viral glycoprotein C (gC) to bind heparan sulfate (HS) on target cells to complete virus attachment. Here, we identified aminoquinoline surfen, a small-molecule antagonist of HS, as a novel and potent antiviral agent against PRV. We demonstrated that surfen not only effectively inhibited PRV infection in multiple permissive pig, human, and mouse cell lines, but also significantly elevated mice survival after lethal PRV challenge. Surfen pre-treatment significantly reduced PRV attachment and infectious virus production in target cells. Enzymatic removal of HS chains by heparinase or addition of exogenous HS counteracted PRV inhibition by surfen, demonstrating that its antiviral activity is dependent on HS. Notably, surfen lost its ability to inhibit the attachment of PRV gC-deficient virus, which enters cells in an HS-independent manner, indicating that the binding of surfen to HS interferes with the interaction between PRV gC and HS on the cell surface. Cumulatively, these findings demonstrate that surfen inhibits PRV attachment by preventing the binding of PRV gC to HS on target cells and reveal that targeted disruption of PRV gC-HS interaction is an effective strategy to develop antiviral drugs to defend PRV infection.IMPORTANCEPseudorabies virus (PRV) causes severe respiratory, reproductive, and neurological disorders in pigs, and its infection in humans is also reported occasionally. PRV is not only a serious concern in veterinary medicine, but also a potential threat to public health. Therefore, the development of effective antiviral agents against PRV is needed to prevent its infection and spread. Here, we demonstrated that aminoquinoline surfen, a small-molecule antagonist of HS, effectively inhibited PRV infection in multiple permissive cell lines
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.